

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3160845

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	SENTINELLA PHARMACEUTICALS, INC.	11/14/2014
RECEIVING PARTY DATA		
Name:	NAICONS SRL	
Street Address:	VIALE ORTLES 22/4	
City:	MILANO	
State/Country:	ITALY	
Postal Code:	20138	
PROPERTY NUMBERS Total: 4		
Property Type	Number	
Application Number:	14007739	
Patent Number:	7307057	
Patent Number:	7319088	
Patent Number:	7351687	
CORRESPONDENCE DATA		
Fax Number:	(703)816-4100	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	703 816-4000	
Email:	ap@nixonvan.com	
Correspondent Name:	NIXON & VANDERHYE PC	
Address Line 1:	901 N. GLEBE ROAD	
Address Line 4:	ARLINGTON, VIRGINIA 22203	
ATTORNEY DOCKET NUMBER:	GRT/3687-350	
NAME OF SUBMITTER:	GARY R. TANIGAWA	
SIGNATURE:	/Gary R. Tanigawa/	
DATE SIGNED:	12/23/2014	
Total Attachments: 6		
source=Assignment#page1.tif		
source=Assignment#page2.tif		
source=Assignment#page3.tif		

source=Assignment#page4.tif

source=Assignment#page5.tif

source=Assignment#page6.tif

ASSIGNMENT

WHEREAS, Sentinella Pharmaceuticals, Inc., a corporation having a place of business at **47 Hulfish Street, Princeton, New Jersey 08542**, hereinafter generally referred to as "**ASSIGNOR**", is the sole and exclusive owner of the inventions, patents, and patent applications as listed on the attached Schedule A.

WHEREAS, Naicons SRL, a corporation having a place of business at **Viale Ortles 22/4, 20138 Milano, Italy**, hereinafter generally referred to as "**ASSIGNEE**," is desirous of acquiring and/or confirming the acquisition of the inventions, patents, and patent applications on the attached Schedule A.

WHEREAS, ASSIGNOR and ASSIGNEE have entered into a certain Agreement, the "**Agreement**", pursuant to which ASSIGNOR has agreed to assign or cause the assignment to ASSIGNEE of certain Intellectual Property including, without limitation, the inventions, patents, and patent applications listed on the attached Schedule A;

WHEREAS, ASSIGNEE is desirous of acquiring and/or confirming the acquisition of the inventions, patents, and patent applications listed on the attached Schedule A.

NOW, THEREFORE, in consideration of good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged and intending to be legally bound hereby, ASSIGNOR, has assigned and/or hereby sells, assigns, transfers, and conveys unto ASSIGNEE; the whole and entire right, title and interest in and to:

all inventions based on the documents listed in attached Schedule A ("**Inventions**");

the patent applications listed in attached Schedule A and any and all United States and foreign patent applications disclosing one or more of the Inventions including, without limitation, applications for patents including provisionals, non-provisionals, divisions, continuations, continuations-in-part, utility models, Patent Cooperation Treaty ("**PCT**") applications and designs and any other related United States and foreign applications and equivalents thereof ("**Applications**"), along with the right to claim priority to the Applications under any treaty relating thereto;

all United States and foreign patents, utility models, inventor's certificates and designs and all equivalents thereof which may be granted for the Inventions or Applications, and post-grant actions including extensions, renewals, reissues and certificates thereof ("**Patents**"); and

all rights to sue for and collect damages resulting from past, present and future infringement of all granted or to be granted Patents.

The Inventions, Applications, and Patents to be held and enjoyed by the ASSIGNEE, for ASSIGNEE's own use and benefit, and for ASSIGNEE's legal representatives and assigns to the full end of the term or terms of said granted or to be granted Patents, as fully and entirely as the same would have been held by ASSIGNOR had this assignment and sale not been made; and for the aforesaid consideration ASSIGNOR hereby covenants, agrees and undertakes to execute or cause to be executed, whenever requested by ASSIGNEE, all patent applications, assignments, declarations lawful oaths and any other papers which ASSIGNEE may deem necessary or desirable for securing to ASSIGNEE or for maintaining for ASSIGNEE all the Inventions, Applications and Patents hereby assigned or agreed to be assigned; all without further compensation to the undersigned ASSIGNOR.

It is agreed that ASSIGNOR shall be legally bound, upon request and at the expense of ASSIGNEE or its successors or assigns or a legal representative thereof, to supply all information and evidence of which the undersigned has knowledge or possession, relating to the making and practicing of the Inventions, and to testify in any legal proceeding relating thereto.

ASSIGNOR hereby represents and warrants that it has full right, power and authority to assign the entire right, title, and interest in the Patents, Applications, and Inventions, based on attached Schedule A and to consummate the assignment contemplated herein. ASSIGNOR also represents and warrants that it has full right, power, and authority to enter into, execute, and deliver this Assignment, the execution and delivery of which have been duly authorized by all necessary action on the part of ASSIGNOR, and no other authorization or proceedings on the part of ASSIGNOR are necessary to authorize this Assignment. This Assignment has been duly executed and delivered and constitutes a valid, binding and enforceable assignment of the entire right, title, and interest in the Patents, Applications, and Inventions based on the attached Schedule A.

ASSIGNOR hereby warrants that no assignment, sale, agreement, or encumbrance has been or will be made or entered into which would conflict with this Assignment.

(SIGNATURE PAGE FOLLOWS – MAY BE SIGNED IN COUNTERPARTS)

Sentinella Pharmaceuticals, Inc.

2014/11/14
(Date)

Lorenzo Pellegrini
NAME: LORENZO PELLEGRINI
TITLE SECRETARY

Diana Franco



Naicons SRL

17.10.2014
(Date)

Stefano Donadio
NAME: STEFANO DONADIO
TITLE MANAGING DIRECTOR

(SCHEDULE A FOLLOWS)

Schedule A

Application No.	Filing Date	Publ. No.	Patent No.	Country	Title
12763052.3	03/30/2012	EP2701718		Europe	LantibioticCarboxyamide Derivatives with Enhanced Antibacterial Activity
14/007,739	09/26/2013	20140094402		United States	Lantibiotic NAI-802, Pharmaceutically Acceptable Salts, Compositions, and uses Thereof
61/469,158	03/30/2011			United States	Lantibiotic NAI-802, Pharmaceutically Acceptable Salts, Compositions and Uses Thereof
61/533,605	09/12/2011			United States	Lantibiotic NAI-802 Pharmaceutically Acceptable Salts, Compositions and Uses Thereof
61/566,250	12/02/2011			United States	Lantibiotic NAI-802, Pharmaceutically Acceptable Salts, Compositions and Uses Thereof
PCT/US2013/031487	03/30/2012	WO2012/135636		PCT	Lantibiotic NAI-802 Pharmaceutically Acceptable Salts, Compositions and Uses Thereof
2,529,124	07/12/2004		2,529,124	Canada	Antibiotic 107891, its factors A1 and A2, Pharmaceutically Acceptable Salts and Compositions and Use thereof
04740916.4	07/12/2004		1646646	France	Antibiotic 107891, its factors A1 and A2, Pharmaceutically Acceptable Salts and Compositions and Use thereof
04740916.4	07/12/2004		1646646	Germany	Antibiotic 107891, its factors A1 and A2, Pharmaceutically Acceptable Salts and Compositions and Use thereof
04740916.4	07/12/2004		1646646	Italy	Antibiotic 107891, its factors A1 and A2, Pharmaceutically Acceptable Salts and Compositions and Use thereof
2006-520724	07/12/2004		4163737	Japan	Antibiotic 107891, its factors A1 and A2, Pharmaceutically Acceptable Salts and Compositions and Use thereof
04740916.4	07/12/2004		1646646	Spain	Antibiotic 107891, its factors A1 and A2, Pharmaceutically Acceptable Salts and Compositions and Use thereof

DB1/ 80803323.1

04740916.4	07/12/2004		1646646	United Kingdom	Antibiotic 107891, its factors A1 and A2, Pharmaceutically Acceptable Salts and Compositions and Use thereof
10/521,336	01/20/2006	20060183673	7,307,057	United States	Antibiotic 107891, its factors A1 and A2, Pharmaceutically Acceptable Salts and Compositions and Use thereof
03016306.7	07/18/2003	EP1646646	1646646	Europe	Antibiotic 107891, its factors A1 and A2, Pharmaceutically Acceptable Salts and Compositions and Use thereof
PCT/EP2004/007658	07/12/2004	WO2005/014628		PCT	Antibiotic 107891, its factors A1 and A2, Pharmaceutically Acceptable Salts and Compositions and Use thereof
PCT/US2013/072307	11/27/2013	WO2014/085637		PCT	New Lantibiotic Derivatives and a Process for Their Preparation
61/731,881	11/30/2012			United States	New Lantibiotic Derivatives and a Process for Their Preparation
2,593,818	01/19/2005			Canada	Antibiotic 107891, its Factors A1 and A2, Pharmaceutically Acceptable Salts and Compositions and Use
5723117.7	01/19/2005		1855705	France	Antibiotic 107891, its Factors A1 and A2, Pharmaceutically Acceptable Salts and Compositions and Use
5723117.7	01/19/2005		1855705	Germany	Antibiotic 107891, its Factors A1 and A2, Pharmaceutically Acceptable Salts and Compositions and Use
5723117.7	01/19/2005		1855705	Italy	Antibiotic 107891, its Factors A1 and A2, Pharmaceutically Acceptable Salts and Compositions and Use
2007-551240	01/19/2005		4189026	Japan	Antibiotic 107891, its Factors A1 and A2, Pharmaceutically Acceptable Salts and Compositions and Use
5723117.7	01/19/2005		1855705	Spain	Antibiotic 107891, its Factors A1 and A2, Pharmaceutically Acceptable Salts and Compositions and Use
5723117.7	01/19/2005		1855705	United Kingdom	Antibiotic 107891, its Factors A1 and A2, Pharmaceutically Acceptable Salts and Compositions and Use
5723117.7	01/19/2005	EP1855705	1855705	Europe	Antibiotic 107891, its Factors

DB1/ 80803523.1

					A1 and A2, Pharmaceutically Acceptable Salts and Compositions and Use
11/035,296	01/12/2005	20050203005	7,319,088	United States	Antibiotic 107891, its Factors A1 and A2, Pharmaceutically Acceptable Salts and Compositions and Use
11/045,628	01/26/2005	20050233952	7,351,687	United States	Antibiotic 107891, its Factors A1 and A2, Pharmaceutically Acceptable Salts and Compositions and Use
PCT/US2005/004843	01/19/2005	WO2006/078988		PCT	Antibiotic 107891, its Factors A1 and A2, Pharmaceutically Acceptable Salts and Compositions and Use

DB1/ 80803323.1

Page 6 of 6